The Slamf3, Slamf5, and Slamf6 receptor-induced pathways to murine lupus
Slamf3、Slamf5 和 Slamf6 受体诱导的小鼠狼疮途径
基本信息
- 批准号:9109553
- 负责人:
- 金额:$ 35.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-08-15 至 2018-07-31
- 项目状态:已结题
- 来源:
- 关键词:Amino Acid SequenceAutoantibodiesAutoimmunityB-LymphocytesCD4 Positive T LymphocytesComplementDendritic CellsDevelopmentDiagnosticDiseaseEngineeringGene FamilyHelper-Inducer T-LymphocyteHumanImmune responseImmunosuppressive AgentsInbred BALB C MiceInstructionLeadLupusMonitorMonoclonal AntibodiesMouse StrainsMusPathogenesisPathologyPathway interactionsPatientsPharmaceutical PreparationsPlayProductionProtein IsoformsRegulatory PathwayResearchResearch PersonnelRoleSignal PathwaySignal TransductionSurfaceSystemic Lupus ErythematosusT-LymphocyteT-Lymphocyte SubsetsTestingTransgenesTranslatingTranslationsTreatment ProtocolsVariantWorkadaptive immunitycongenicdesignin vivoindexinginnovationnew therapeutic targetnovelprogramsreceptorresearch studyspecific biomarkerstool
项目摘要
PROJECT SUMMARY (See instructions):
SLAMF receptors and their adapters SAP and EAT-2 play a major role in human and mouse innate and adaptive immune response. Investigators in this Program Project have discovered that in mice several of these receptors either positively or negatively regulate the development of autoimmunity, including lupus related pathology. Excitingly, preliminary studies have revealed deviations in signaling pathways initiated by several SLAMF receptors in immunocytes isolated from patients with systemic lupus erythematosus (SLE).
The overall hypothesis of Project #1 is that the mouse receptors Slamf3, 5, and 6 and their isoforms govern immune responses involved in the pathogenesis of murine lupus. The experiments that are designed to test this hypothesis are grouped as follows:
Specific Aim#1: Testing the hypothesis that the three Slamf6 receptor isoforms initiate distinct positive and negative regulatory pathways to lupus.
Specific Aim #2: Testing the hypothesis that the Slamf5 receptor governs signaling in T and B cells and DC during the pathogenesis of mouse lupus.
Specific Aim #3: Testing the hypothesis that Slamf3 receptor initiated signaling controls autoantibody production.
项目总结(见说明):
SLAMF受体及其衔接子SAP和EAT-2在人类和小鼠先天性和适应性免疫应答中起主要作用。该计划项目的研究人员发现,在小鼠中,这些受体中的几种正或负调节自身免疫的发展,包括狼疮相关的病理。令人兴奋的是,初步研究揭示了从系统性红斑狼疮(SLE)患者分离的免疫细胞中由几种SLAMF受体启动的信号通路的偏差。
项目#1的总体假设是小鼠受体Slamf 3、5和6及其同种型控制参与鼠狼疮发病机制的免疫应答。为检验这一假设而设计的实验分组如下:
具体目标#1:测试三种Slamf 6受体亚型启动狼疮不同的阳性和阴性调节途径的假设。
具体目标#2:测试Slamf 5受体在小鼠狼疮发病过程中控制T和B细胞以及DC中的信号传导的假设。
具体目标#3:检验Slamf 3受体启动信号传导控制自身抗体产生的假设。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CORNELIS P TERHORST其他文献
CORNELIS P TERHORST的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CORNELIS P TERHORST', 18)}}的其他基金
Primary Immuno-Deficiencies Affecting Specific Stages of the Immune Response
影响免疫反应特定阶段的原发性免疫缺陷
- 批准号:
8296689 - 财政年份:2009
- 资助金额:
$ 35.1万 - 项目类别:
Primary Immuno-Deficiencies Affecting Specific Stages of the Immune Response
影响免疫反应特定阶段的原发性免疫缺陷
- 批准号:
7560933 - 财政年份:2009
- 资助金额:
$ 35.1万 - 项目类别:
Role of SAP (SH2D1A) gene in T cell-dependent antibody response
SAP (SH2D1A) 基因在 T 细胞依赖性抗体反应中的作用
- 批准号:
7614096 - 财政年份:2009
- 资助金额:
$ 35.1万 - 项目类别:
Primary Immuno-Deficiencies Affecting Specific Stages of the Immune Response
影响免疫反应特定阶段的原发性免疫缺陷
- 批准号:
8102821 - 财政年份:2009
- 资助金额:
$ 35.1万 - 项目类别:
Primary Immuno-Deficiencies Affecting Specific Stages of the Immune Response
影响免疫反应特定阶段的原发性免疫缺陷
- 批准号:
7882569 - 财政年份:2009
- 资助金额:
$ 35.1万 - 项目类别:
Primary Immuno-Deficiencies Affecting Specific Stages of the Immune Response
影响免疫反应特定阶段的原发性免疫缺陷
- 批准号:
8501241 - 财政年份:2009
- 资助金额:
$ 35.1万 - 项目类别:
SLAM Gene Family Controlled Pathways to SLE
SLAM 基因家族控制 SLE 通路
- 批准号:
7275918 - 财政年份:2006
- 资助金额:
$ 35.1万 - 项目类别:
相似海外基金
Defining the cellular origin of pathogenic autoantibodies
定义致病性自身抗体的细胞起源
- 批准号:
EP/Y031091/1 - 财政年份:2024
- 资助金额:
$ 35.1万 - 项目类别:
Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
- 批准号:
MR/Y022947/1 - 财政年份:2024
- 资助金额:
$ 35.1万 - 项目类别:
Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 35.1万 - 项目类别:
Operating Grants
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
肿瘤衍生新表位的自身抗体作为生物标志物和免疫 PET 试剂用于小细胞肺癌的早期检测
- 批准号:
10715807 - 财政年份:2023
- 资助金额:
$ 35.1万 - 项目类别:
Role of pharmacological activity of autoantibodies in ME/CFS
自身抗体药理活性在 ME/CFS 中的作用
- 批准号:
MR/Y003667/1 - 财政年份:2023
- 资助金额:
$ 35.1万 - 项目类别:
Research Grant
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
- 批准号:
10740682 - 财政年份:2023
- 资助金额:
$ 35.1万 - 项目类别:
Pathogenesis of idiopathic nephrotic syndrome: defining the role of B cells and autoantibodies reactive to podocyte proteins
特发性肾病综合征的发病机制:定义 B 细胞和足细胞蛋白反应性自身抗体的作用
- 批准号:
487849 - 财政年份:2023
- 资助金额:
$ 35.1万 - 项目类别:
Operating Grants
Analysis of pathogenesis associated with mutation of complement associated gene and autoantibodies in development/progression of C3 nephropathy.
补体相关基因突变和自身抗体在C3肾病发生/进展中的发病机制分析。
- 批准号:
22K08309 - 财政年份:2022
- 资助金额:
$ 35.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Depleting autoantibodies for the treatment of autoimmunity
消耗自身抗体来治疗自身免疫
- 批准号:
10481071 - 财政年份:2022
- 资助金额:
$ 35.1万 - 项目类别:














{{item.name}}会员




